日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT

贝拉西普与环孢素类免疫抑制治疗后移植前供体特异性抗体水平的降低:BENEFIT 和 BENEFIT-EXT 研究的事后分析

Bray, R A; Gebel, H M; Townsend, R; Roberts, M E; Polinsky, M; Yang, L; Meier-Kriesche, H-U; Larsen, C P

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

贝拉西普治疗组与环孢素治疗组肾移植受者中新发供体特异性抗体:随机III期BENEFIT和BENEFIT-EXT研究的事后分析

Bray, R A; Gebel, H M; Townsend, R; Roberts, M E; Polinsky, M; Yang, L; Meier-Kriesche, H-U; Larsen, C P

Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept

经验教训:贝拉西普治疗钙调神经磷酸酶抑制剂和避免使用皮质类固醇的随机试验提前终止

Newell, K A; Mehta, A K; Larsen, C P; Stock, P G; Farris, A B; Mehta, S G; Ikle, D; Armstrong, B; Morrison, Y; Bridges, N; Robien, M; Mannon, R B

Increased Pretransplant Frequency of CD28(+) CD4(+) T(EM) Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients

移植前CD28(+)CD4(+)T(EM)细胞频率增加可预测人类肾移植受者发生贝拉西普耐药性排斥反应

Cortes-Cerisuelo, M; Laurie, S J; Mathews, D V; Winterberg, P D; Larsen, C P; Adams, A B; Ford, M L

The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques

耐受性的临界点:在恒河猴中诱导稳定的多系混合嵌合体,但存在巨细胞病毒再激活和疾病的显著风险

Zheng, H B; Watkins, B; Tkachev, V; Yu, S; Tran, D; Furlan, S; Zeleski, K; Singh, K; Hamby, K; Hotchkiss, C; Lane, J; Gumber, S; Adams, A B; Cendales, L; Kirk, A D; Kaur, A; Blazar, B R; Larsen, C P; Kean, L S

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant

按亚型划分的扩大标准供肾的疗效和安全性结果:BENEFIT-EXT 研究移植后 7 年的亚组分析

Florman, S; Becker, T; Bresnahan, B; Chevaile-Ramos, A; Carvalho, D; Grannas, G; Muehlbacher, F; O'Connell, P J; Meier-Kriesche, H U; Larsen, C P

Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function

贝拉西普联合短暂性钙调神经磷酸酶抑制剂治疗可预防排斥反应并促进肾移植长期功能的改善。

Adams, A B; Goldstein, J; Garrett, C; Zhang, R; Patzer, R E; Newell, K A; Turgeon, N A; Chami, A S; Guasch, A; Kirk, A D; Pastan, S O; Pearson, T C; Larsen, C P

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly

一项随机 II 期研究对肾移植受者进行了为期十年的随访,分别给予贝拉西普每 4 周一次或每 8 周一次的治疗。

Vincenti, F; Blancho, G; Durrbach, A; Grannas, G; Grinyó, J; Meier-Kriesche, H-U; Polinsky, M; Yang, L; Larsen, C P

Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection

在非人灵长类动物肾移植模型中,抗白细胞功能相关抗原1疗法治疗共刺激阻断抵抗性排斥反应

Anderson, D J; Lo, D J; Leopardi, F; Song, M; Turgeon, N A; Strobert, E A; Jenkins, J B; Wang, R; Reimann, K A; Larsen, C P; Kirk, A D

Pathogen Stimulation History Impacts Donor-Specific CD8(+) T Cell Susceptibility to Costimulation/Integrin Blockade-Based Therapy

病原体刺激史影响供体特异性CD8(+) T细胞对基于共刺激/整合素阻断疗法的敏感性

Badell, I R; Kitchens, W H; Wagener, M E; Lukacher, A E; Larsen, C P; Ford, M L